Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy
Kathrin Hessling, Caroline Brand, Christian Schwöppe, Mirjam Gerwing, Stefanie Pavelka, Andrew F. Berdel, Heike Hintelmann, Rainer Hamacher, Carsten Müller-Tidow, Gerlinde Egerer, Wolfgang Hartmann, Inga Grünewald, Lars H. Lindner, Dorit Di Gioia, Judith S. Hecker, Sabine Maurer
TL;DR
This study explores combining trabectedin and tTF-NGR to treat advanced soft tissue sarcomas, focusing on safety and effectiveness.
Contribution
The study identifies a recommended dose combination of trabectedin and tTF-NGR for further clinical testing.
Findings
A dose of trabectedin 1.5 mg/m² and tTF-NGR 1.0 mg/m² represents the maximum tolerated dose.
The recommended starting dose is trabectedin 1.5 mg/m² and tTF-NGR 0.5 mg/m² with no dose-limiting toxicity observed.
Higher doses of tTF-NGR led to grade 3 dose-limiting toxicities including cardiac and thromboembolic events.
Abstract
Trabectedin is standard for r/r soft tissue sarcomas. tTF-NGR accumulates in tumor vasculature leading to tumor vascular occlusion and tumor infarction. Both compounds in sequence could trap trabectedin inside tumors and increase its efficacy, which then optimizes the pro-coagulatory activity of tTF-NGR. This report summarizes translational data and results of the safety run-in patient cohort of the TRABTRAP trial combining trabectedin plus tTF-NGR. A dose of trabectedin of 1.5 mg/m2 (24 h, day 1) combined with 1.0 mg/m2 of tTF-NGR (1 h, days 2 and 3, q day 22) represents the approx. Maximum tolerated dose (MTD) and with 0.5 mg/m2 tTF-NGR (days 2 and 3) the recommended starting dose for the randomized part of TRABTRAP. None of the 6 patients on 0.5 mg/m2 tTF-NGR had dose-limiting toxicity (DLT). Higher doses or additional days of application of tTF-NGR led to grade 3 DLT including early…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPeptidase Inhibition and Analysis · Sarcoma Diagnosis and Treatment · Protein Degradation and Inhibitors